IRINOTECAN AS A THIRD-LINE TREATMENT OF ADVANCED GASTRIC CANCER AFTER FAILURE OF FLUOROPYRIMIDINE, PLATINUM, AND TAXANES

被引：0
|
作者：
Nishimura, Takashi
Iwasa, Satoru
Shoji, Hirokazu
Okita, Natsuko
Takashima, Atsuo
Honma, Yoshitaka
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shimada, Yasuhiro
机构：
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1-17-5
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer
    Zhong, Haijun
    Zhang, Yiping
    Ma, Shenglin
    Ying, Jie-Er
    Yang, Yunshan
    Yong, Dong
    Hang, Xiaosheng
    Sun, Qing
    Zhong, Baoliang
    Wang, Daoyuan
    ANTI-CANCER DRUGS, 2008, 19 (10) : 1013 - 1018
  • [22] Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer
    Kimura, Michio
    Usami, Eiseki
    Kanematsu, Tetsufumi
    Iwai, Mina
    Yoshimura, Tomoaki
    Mori, Hiromi
    Sugiyama, Tadashi
    Teramachi, Hitomi
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 466 - 472
  • [23] Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review
    Chan, Wing-lok
    Lam, Ka-on
    So, Tsz-him
    Lee, Victor Ho-fun
    Kwong, Lai-wan Dora
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [24] Efficacy and safety of irinotecan monotherapy as third line treatment for advanced gastric cancer
    Kawakami, Takeshi
    Machida, Nozomu
    Kawahira, Masahiro
    Kawai, Sadayuki
    Kito, Yosuke
    Yoshida, Yukio
    Hamauchi, Satoshi
    Tsushima, Takahiro
    Todaka, Akiko
    Yamazaki, Kentaro
    Yokota, Tomoya
    Fukutomi, Akira
    Onozawa, Yusuke
    Yasui, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [25] Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
    Kohei Shitara
    Keitaro Matsuo
    Ayako Mizota
    Chihiro Kondo
    Motoo Nomura
    Daisuke Takahari
    Tomoya Yokota
    Takashi Ura
    Seiji Ito
    Akira Sawaki
    Masahiro Tajika
    Hiroki Kawai
    Kei Muro
    Gastric Cancer, 2011, 14 : 155 - 160
  • [26] Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
    Shitara, Kohei
    Matsuo, Keitaro
    Mizota, Ayako
    Kondo, Chihiro
    Nomura, Motoo
    Takahari, Daisuke
    Yokota, Tomoya
    Ura, Takashi
    Ito, Seiji
    Sawaki, Akira
    Tajika, Masahiro
    Kawai, Hiroki
    Muro, Kei
    GASTRIC CANCER, 2011, 14 (02) : 155 - 160
  • [27] Clinical impact of oral intake in third-line treatment for advanced gastric cancer
    Ogata, T.
    Narita, Y.
    Kumanishi, R.
    Nakazawa, T.
    Matsubara, Y.
    Kato, K.
    Nozawa, K.
    Honda, K.
    Masuishi, T.
    Bando, H.
    Kadowaki, S.
    Ando, M.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S141 - S141
  • [28] Irinotecan Plus Capecitabine as a Second-line Treatment after Failure of 5-Fluorouracil and Platinum in Patients with Advanced Gastric Cancer
    Sun, Qing
    Hang, Meng
    Xu, Wei
    Mao, Weidong
    Hang, Xiaosheng
    Li, Maoquan
    Zhang, Jiaxing
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (12) : 791 - 796
  • [29] Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan
    Kang, Byung Woog
    Kim, Jong Gwang
    Kwon, Oh-Kyoung
    Chung, Ho Young
    Yu, Wansik
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (18) : 5396 - 5402
  • [30] Non-platinum-based chemotherapy for treatment of advanced gastric cancer:5-fluorouracil,taxanes,and irinotecan
    Byung Woog Kang
    Jong Gwang Kim
    Oh-Kyoung Kwon
    Ho Young Chung
    Wansik Yu
    World Journal of Gastroenterology, 2014, 20 (18) : 5396 - 5402
12345